Stay updated on Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page
- Check2 days agoChange DetectedThe page now renders a 403 Forbidden error with the basic HTML header and a Home link, replacing the previous study-record content; several navigation and document-related sections are removed in this view.SummaryDifference20%

- Check9 days agoChange DetectedA new revision tag v3.7.0 has been added, replacing the previous v3.6.6 to record an updated page revision.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page's revision label was updated from v3.6.5 to v3.6.6, indicating a minor update to the documentation/version history.SummaryDifference0.0%

- Check30 days agoChange DetectedA new funding identifier '2015 ( U.S. NIH Grant/Contract )' was added next to the study identifiers, indicating NIH support for the trial. The addition provides funding context but does not change the study design or eligibility.SummaryDifference0.0%

- Check44 days agoChange DetectedThe page's revision metadata was updated to version v3.6.5 with August 2026 timestamps, indicating a maintenance update rather than substantive changes to study content.SummaryDifference0.2%

- Check66 days agoChange DetectedThe page's revision was updated from v3.6.3 to v3.6.4. This appears to be a minor maintenance update that does not change study data or content.SummaryDifference0.0%

Stay in the know with updates to Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.